Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla Sells 155,333 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla sold 155,333 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $121,159.74. Following the sale, the chief executive officer now directly owns 1,736,883 shares in the company, valued at $1,354,768.74. This trade represents a 8.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Spero Therapeutics Price Performance

NASDAQ SPRO traded up $0.12 during midday trading on Wednesday, hitting $0.88. 1,489,743 shares of the company traded hands, compared to its average volume of 292,584. The company’s 50-day simple moving average is $0.99 and its 200-day simple moving average is $1.19. Spero Therapeutics, Inc. has a 52 week low of $0.74 and a 52 week high of $1.89. The company has a market cap of $47.81 million, a PE ratio of 12.53 and a beta of 0.61.

Analyst Upgrades and Downgrades

Several analysts recently commented on SPRO shares. Evercore ISI lowered Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a report on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Spero Therapeutics in a research report on Thursday, January 30th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.